Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 19, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Viktoria Blumenberg1, Caroline Diorio2, Jordan Gauthier3

  • 1Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts.

Transplantation and Cellular Therapy
|May 17, 2026
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential cytokine architecture in patients treated with CART19 versus CART22.

Journal for immunotherapy of cancer·2026
Same author

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal for immunotherapy of cancer·2026
Same author

Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia.

Cytotherapy·2026
Same author

Nonviral Gold Nanoparticle-Mediated Delivery of CRISPR-Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells.

Advanced nanobiomed research·2026
Same author

Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Perturbation of the preterm human immune system in early life.

JCI insight·2026
Summary
This summary is machine-generated.

Standardized biomarker testing in CAR T-cell therapy is crucial for consistent results and improved patient care. These recommendations harmonize assay practices to guide treatment and manage toxicity effectively.

Area of Science:

  • Immunotherapy
  • Hematologic Malignancies
  • Biomarker Discovery

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy has transformed hematologic malignancy treatment.
  • Inconsistent biomarker assays hinder comparability, translational insights, and evidence-based decisions.
  • Standardized frameworks are vital as CAR T-cell therapy expands to new platforms and indications.

Purpose of the Study:

  • To establish harmonized biomarker testing practices for CAR T-cell therapy.
  • To provide evidence-based recommendations on biomarker selection, timing, and application.
  • To inform toxicity management, guide treatment decisions, and support future research.

Main Methods:

  • A multidisciplinary expert panel reviewed current literature and clinical practices.
Keywords:
BiomarkerChimeric antigen receptor T-cell therapyImmune effector cellsLaboratory testingToxicity

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: May 19, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

  • Consensus was reached on recommendations for laboratory assessments, cytokine profiling, and CAR T-cell monitoring.
  • Biomarkers were tiered into 'must-have,' 'can-have,' and 'nice-to-have' categories.

    • Main Results:

    • Comprehensive baseline laboratory testing is recommended before lymphodepletion.
    • Serial measurements of inflammatory markers and cytokines are advised during toxicity phases.
    • CAR T-cell monitoring should be performed at defined intervals; cytokines and CAR-T kinetics may predict toxicity or non-response.

    Conclusions:

    • Standardized biomarker testing is essential for improving patient outcomes and advancing CAR T-cell therapy.
    • These recommendations offer a framework for clinical implementation and future research.
    • Harmonized practices bridge routine care with next-generation biomarker-driven strategies.